Clinical Trials Logo

Filter by:
NCT ID: NCT00770510 Completed - Primary Insomnia Clinical Trials

A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

Start date: September 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.

NCT ID: NCT00769782 Completed - Metastatic Cancer Clinical Trials

Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

GISTs
Start date: October 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Surgery may be an effective treatment for liver metastasis from a gastrointestinal stromal tumor. PURPOSE: This phase II trial is studying how well surgery works in treating patients with liver metastasis from a gastrointestinal stromal tumor.

NCT ID: NCT00769496 Completed - Hyperphosphatemia Clinical Trials

BAY 77-1931 Long-term Extension From Phase II Study

Start date: January 2005
Phase: Phase 2
Study type: Interventional

A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis

NCT ID: NCT00768885 Completed - Myopia Clinical Trials

Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs.

Start date: September 2008
Phase: N/A
Study type: Interventional

To evaluate the wearing satisfaction of a new design of the PureVision soft contact lenses.

NCT ID: NCT00768755 Completed - Clinical trials for Carcinoma, Non-Small Cell Lung

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

Start date: January 2009
Phase: Phase 1/Phase 2
Study type: Interventional

AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

NCT ID: NCT00768560 Completed - Hypertension Clinical Trials

Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, 6 x 3 cross-over study. All patients who meet the entry criteria will be required to stop taking any other anti-hypertensive agents than Adalat CR (controlled release), if taken, before starting 4 weeks (±7days) open-label Adalat CR 40 mg once daily (OD) treatment phase (baseline treatment period). Of them, those who are confirmed with their eligibility as subjects for the present study at the end of the baseline treatment period will be randomly allocated to one of the 6 treatment sequences on the basis of a computer-generated randomization list. Subsequently, BAY A1040 CR tablet 40 mg OD, 40 mg twice daily (BID) or 80 mg OD will be administered to a total of 6 weeks, 2 weeks per each treatment period (Period 1-3) under double-blind conditions using BAY A1040 CR tablet 40 mg and its placebo as follows (Double-blind treatment period).

NCT ID: NCT00768469 Completed - Clinical trials for Advanced Malignant Solid Tumors

Study Evaluating Safety And Tolerability, Solid Tumor

Start date: October 2008
Phase: Phase 1
Study type: Interventional

This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.

NCT ID: NCT00767637 Completed - Hyperphosphatemia Clinical Trials

Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

Start date: June 2005
Phase: Phase 2
Study type: Interventional

To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis

NCT ID: NCT00767052 Completed - Healthy Volunteer Clinical Trials

Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of multiple ascending oral doses of AZD1236 given to healthy young subjects for 13 days and to evaluate the single-dose relative bioavailability of the oral suspension and oral tablet formulations.

NCT ID: NCT00766545 Completed - Cerebral Infarction Clinical Trials

Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.

CSPS
Start date: April 1992
Phase: Phase 3
Study type: Interventional

The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in preventing the recurrence of cerebral infarction in patients who had suffered a cerebral infarction 1 to 6 months prior to entering the trial.